Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher's Acquisition of Dionex Clears Antitrust Waiting Period

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Thermo Fisher Scientific said today that its proposed $2.1 billion acquisition of chromatography firm Dionex has cleared the mandatory, pre-merger waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

Thermo said it is in the process of "seeking similar clearances under antitrust laws of other jurisdictions," and expects to complete the acquisition later in the quarter.

The company in December announced plans to acquire Dionex for $118.50 per share in cash, which represented a 21 percent premium to Dionex's closing share price of $98.17 on Dec. 10, the last trading day prior to the announcement.

Dionex shares were trading at $117.95 Monday afternoon.

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.